Published in Antimicrob Agents Chemother on July 01, 1992
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol (1994) 5.36
Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro. Antimicrob Agents Chemother (1997) 1.23
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1996) 1.16
pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother (1993) 1.14
The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology (2009) 1.05
Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother (2011) 1.04
Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother (1996) 1.03
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology (2011) 0.98
Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob Agents Chemother (1998) 0.95
In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother (1997) 0.95
Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother (1994) 0.93
Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrob Agents Chemother (1993) 0.92
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother (1994) 0.92
The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother (2014) 0.84
Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob Agents Chemother (1998) 0.78
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. Antimicrob Agents Chemother (1994) 0.75
The Chinese herb-derived Sparstolonin B suppresses HIV-1 transcription. Virol J (2015) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 15.19
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 14.63
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med (1989) 10.74
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Molecular targets for AIDS therapy. Science (1990) 4.28
Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21
Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet (1988) 3.37
Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother (1992) 3.11
Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr (1990) 2.90
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med (1990) 2.52
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1987) 2.24
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med (1992) 2.19
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med (1989) 2.17
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A (1987) 1.96
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA (1989) 1.84
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med (1990) 1.81
Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med (1989) 1.68
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood (1991) 1.12
A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr (1991) 0.80
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci (2001) 4.33
Macrophages and age-dependent resistance to Herpes simplex virus in mice. J Immunol (1970) 4.15
Decision analysis for best management of mildly dyskaryotic smear. Lancet (1993) 4.15
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med (1996) 4.03
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature (1993) 3.73
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol (1981) 3.71
Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet (1985) 3.50
Selective effects of anti-macrophage serum, silica and anti-lymphocyte serum on pathogenesis of herpes virus infection of young adult mice. J Immunol (1970) 3.49
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Fos expression in orexin neurons varies with behavioral state. J Neurosci (2001) 3.08
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem (1981) 3.01
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
Melanopsin in cells of origin of the retinohypothalamic tract. Nat Neurosci (2001) 2.79
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother (1991) 2.66
Herpes simplex encephalitis: vidarabine therapy and diagnostic problems. N Engl J Med (1981) 2.56
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med (1990) 2.50
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol (1976) 2.42
Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect Dis (1980) 2.41
Primary human T-lymphotropic virus type III infection. Ann Intern Med (1985) 2.40
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
Diseases that mimic herpes simplex encephalitis. Diagnosis, presentation, and outcome. NIAD Collaborative Antiviral Study Group. JAMA (1989) 2.38
Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS. Ann Neurol (1986) 2.37
A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem (1977) 2.32
Immunopathology of lymphocytic choriomeningitis viurs infection of newborn mice. Antithymocyte serum effects on glomerulonephritis and wasting disease. J Exp Med (1968) 2.31
Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 2.30
Interaction of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus. J Infect Dis (1977) 2.30
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene (2009) 2.27
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1994) 2.24
Human immunodeficiency virus (HIV) infection of the uterine cervix. Ann Intern Med (1988) 2.17
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
Viability and functional activity of cryopreserved mononuclear cells. Clin Diagn Lab Immunol (2000) 2.05
Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A (1999) 2.02
Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). N Engl J Med (1985) 1.99
Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet (1986) 1.96
Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis (1991) 1.93
Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med (1998) 1.88
Effects of anti-lymphoid sera on viral infections. Lancet (1968) 1.87
Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother (1996) 1.86
Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci U S A (1972) 1.85
Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses (1992) 1.85
Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med (1979) 1.83
Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med (1985) 1.83
Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis (1981) 1.81
Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis (1988) 1.81
Infrequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med (1985) 1.78
Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med (1981) 1.77
Unusual electrocardiographic manifestation of pulmonary embolism. Am Heart J (1970) 1.74
Infection of human endothelial cells by human T-lymphotropic virus type I. Proc Natl Acad Sci U S A (1984) 1.73
Effects of anti-thymocyte serum on lymphocytic choriomeningitis (LCM) virus infection in mice. Proc Soc Exp Biol Med (1967) 1.71
Replication of herpes simplex virus and cytomegalovirus in human leukocytes. J Immunol (1978) 1.69
Functional properties of T lymphocytes and their subsets in cytomegalovirus mononucleosis. J Immunol (1983) 1.67
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis (2000) 1.64
Contrasting effects of ibotenate lesions of the paraventricular nucleus and subparaventricular zone on sleep-wake cycle and temperature regulation. J Neurosci (2001) 1.62
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol (1993) 1.61
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst (1998) 1.60
Antibody to lymphadenopathy-associated virus in AIDS. N Engl J Med (1985) 1.59
Isolation patterns of the human immunodeficiency virus from cervical secretions during the menstrual cycle of women at risk for the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.59
Methylation of the viral genome in an in vitro model of herpes simplex virus latency. Proc Natl Acad Sci U S A (1982) 1.56
Leukemia virus activation in chronic allogeneic disease. Proc Natl Acad Sci U S A (1970) 1.55
Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrob Agents Chemother (1986) 1.51